BioNTech SE
BNTX evidence brief
What we can confirm
- Market Cap:
- $24.78B
What it means
What to watch
Prepared research question
What matters most for BNTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BNTX
BioNTech SE (BNTX) is a German biotechnology company transitioning from its COVID-19 vaccine success to build a multi-product oncology pipeline, with 33 active clinical trials and a substantial cash reserve.
Key risk: Declining COVID-19 revenue
Market Cap
$24.78B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Tracking 78 clinical trials for BioNTech SE.
BioNTech SE (BNTX) is a German biotechnology company transitioning from its COVID-19 vaccine success to build a multi-product oncology pipeline, with 33 active clinical trials and a substantial cash reserve.
- BioNTech is pivoting from COVID-19 to oncology with 33 clinical trials and $19B in cash [news · 2026-10-04].
- The company expects 2026 to be a catalyst-rich year with seven late-stage data readouts and 15 Phase 3 trials ongoing by year-end [news · 2026-01-12].
- Gotistobart produced a clinically meaningful overall-survival benefit in the Phase 3 PRESERVE-003 trial for metastatic squamous non-small cell lung cancer [news · 2026-09-15].
- BNT324 has advanced to a Phase III trial in metastatic castration-resistant prostate cancer [news · 2026-01-28].
- BioNTech and Bristol Myers Squibb reported interim Phase 2 data from the ROSETTA Lung-02 study evaluating pumitamig plus chemotherapy [news · 2026-06-09].
What works
- BioNTech has a deep cash reserve of $19B, providing financial stability to fund its extensive oncology pipeline [news · 2026-10-04].
- The company has a broad late-stage pipeline with 15 Phase 3 trials expected by end of 2026, covering multiple tumor types [news · 2026-01-12].
- Gotistobart nearly doubled survival compared to standard-of-care chemotherapy in a Phase 3 lung cancer trial, indicating strong clinical potential [news · 2026-09-15].
What to weigh
- COVID-19 vaccine revenue is declining, putting pressure on the company to successfully commercialize its oncology assets [news · 2026-08-04].
- Key pipeline data for pumitamig is not expected until after 2028, creating a long wait for potential catalysts [news · 2026-10-04].
- The company revised its 2026 guidance downward, reflecting ongoing revenue challenges [news · 2026-08-04].
From the filings
Quoted directly from source documents.
BioNTech is pivoting from COVID-19 to oncology with 33 trials and $19B cash.
“BioNTech pivots from Covid windfall to oncology with 33 trials and $19B cash; key pumitamig data post-2028.”
News · October 4, 2026
2026 is expected to be a catalyst-rich year with seven late-stage data readouts.
“Expected 2026 oncology milestones include seven late-stage data readouts and to have 15 Phase 3 clinical trials ongoing by year end”
News · January 12, 2026
Gotistobart produced a clinically meaningful overall-survival benefit in Phase 3.
“BioNTech SE (NASDAQ:BNTX) reported that its investigational lung-cancer drug gotistobart produced a clinically meaningful overall-survival benefit in the Phase 3 PRESERVE-003 trial”
News · September 15, 2026
BNT324 advanced to Phase III in prostate cancer.
“BioNTech has initiated a Phase III clinical trial for its oncology candidate BNT324 in metastatic castration-resistant prostate cancer”
News · January 28, 2026
Risks & what to watch (3)›
Key risks
- Declining COVID-19 revenue — COVID-19 vaccine revenue is declining, pressuring the company to successfully commercialize oncology assets [news · 2026-08-04].
- Long wait for pumitamig data — Key pumitamig data not expected until after 2028, creating a long period without major catalysts [news · 2026-10-04].
- Revised 2026 guidance — The company revised its 2026 guidance downward, reflecting ongoing revenue challenges [news · 2026-08-04].
What to watch
- Seven late-stage data readouts expected in 2026 across immunomodulators, ADCs, and mRNA immunotherapies [news · 2026-01-12].
- 15 Phase 3 clinical trials ongoing by end of 2026, covering multiple tumor types [news · 2026-01-12].
- Additional late-stage trial readouts through 2030+ that could create multiple launch opportunities [news · 2026-01-12].
- Deployment of $19B cash reserve to fund late-stage pipeline and potential business development [news · 2026-10-04].
Sources: Catalysts · News · SEC filings · Generated October 12, 2026 · How we verify sources →
Run BioNTech SE through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available BioNTech SE facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Short Interest
as of May 20, 2026- % of float
- 3.2%
- Days to cover
- 2.6
- Shares short
- 2,215,111
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BNTX short interestGovernance
Frequently asked questions
What is the AI investment thesis for BioNTech SE?
BioNTech SE (BNTX) is a German biotechnology company transitioning from its COVID-19 vaccine success to build a multi-product oncology pipeline, with 33 active clinical trials and a substantial cash reserve.
Who is the CEO of BioNTech SE?
Dr. Ugur Sahin M.D. is the chief executive officer of BioNTech SE (BNTX).
Where is BioNTech SE headquartered?
BioNTech SE (BNTX) is headquartered in Mainz, Germany.
What therapeutic areas does BioNTech SE focus on?
BioNTech SE develops therapies across Oncology, Gene Therapy, Immunology, Infectious Disease, Respiratory.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.